NCT04481685View on ClinicalTrials.gov

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

February 25, 2021

Study Completion Date

June 1, 2021

Conditions
Covid19
Interventions
DRUG

ATI-450

50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.

DRUG

Placebo

Placebo pill will be taken twice daily preferably spaced 12 hours apart.

Trial Locations (1)

66160

The University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT04481685 - A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter